HBK Sorce Advisory’s Acutus Medical Inc AFIB Stock Holding History

HBK Sorce Advisory’s Portfolio AFIB Stock Details AFIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-30,000	Closed	-$6.06K	–	634
2023 Q4	$6.06K	Buy	+30,000	New	+$11.8K	﹤0.01%	566

Other funds holding AFIB

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HBK Sorce Advisory's AFIB Position: Q1 2024 in Review

HBK Sorce Advisory sold out of Acutus Medical Inc (AFIB) in Q1 2024, closing a stake of 30,000 shares — an estimated $6.06K sold.

HBK Sorce Advisory first reported a position in AFIB in Q4 2023 and held it in 1 quarter. The position peaked at $6.06K in Q4 2023. 23 funds tracked by Wall St. Rank hold AFIB as of Q1 2024.

HBK Sorce Advisory reported no remaining Acutus Medical Inc position as of Q1 2024 after selling out during the quarter.
HBK Sorce Advisory sold 30,000 Acutus Medical Inc shares in Q1 2024, an estimated $6.06K.
HBK Sorce Advisory first reported a position in Acutus Medical Inc in Q4 2023 and held it in 1 quarter.
HBK Sorce Advisory's Acutus Medical Inc position peaked at $6.06K in Q4 2023.
23 funds tracked by Wall St. Rank held Acutus Medical Inc as of Q1 2024.

Based on HBK Sorce Advisory's 13F filing for Q1 2024, filed 9 May 2024.